255 related articles for article (PubMed ID: 24870719)
21. Immuno-PET imaging of tumor endothelial marker 8 (TEM8).
Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM
Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190
[TBL] [Abstract][Full Text] [Related]
22. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS
Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672
[TBL] [Abstract][Full Text] [Related]
24. In Vitro and In Vivo Characterization of
Allen KJH; Jiao R; Li J; Beckford-Vera DR; Dadachova E
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235126
[No Abstract] [Full Text] [Related]
25. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
26. Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
Warnders FJ; Waaijer SJ; Pool M; Lub-de Hooge MN; Friedrich M; Terwisscha van Scheltinga AG; Deegen P; Stienen SK; Pieslor PC; Cheung HK; Kosterink JG; de Vries EG
J Nucl Med; 2016 May; 57(5):812-7. PubMed ID: 26848172
[TBL] [Abstract][Full Text] [Related]
27. A radiopharmaceutical [
Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
[TBL] [Abstract][Full Text] [Related]
28. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
[No Abstract] [Full Text] [Related]
29.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
30. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by
Chomet M; Schreurs M; Nguyen M; Howng B; Villanueva R; Krimm M; Vasiljeva O; van Dongen GAMS; Vugts DJ
Theranostics; 2020; 10(13):5815-5828. PubMed ID: 32483421
[TBL] [Abstract][Full Text] [Related]
31. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
32. Tumor uptake and tumor/blood ratios for [
Al-Saden N; Cai Z; Reilly RM
Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
[TBL] [Abstract][Full Text] [Related]
33. Molecular imaging of T cell co-regulator factor B7-H3 with
Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM
Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047
[TBL] [Abstract][Full Text] [Related]
34. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Wang S; Li J; Hua J; Su Y; Beckford-Vera DR; Zhao W; Jayaraman M; Huynh TL; Zhao N; Wang YH; Huang Y; Qin F; Shen S; Gioeli D; Dreicer R; Sriram R; Egusa EA; Chou J; Feng FY; Aggarwal R; Evans MJ; Seo Y; Liu B; Flavell RR; He J
Clin Cancer Res; 2021 Mar; 27(5):1305-1315. PubMed ID: 33293372
[TBL] [Abstract][Full Text] [Related]
35. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
36. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer.
England CG; Kamkaew A; Im HJ; Valdovinos HF; Sun H; Hernandez R; Cho SY; Dunphy EJ; Lee DS; Barnhart TE; Cai W
Mol Pharm; 2016 Jun; 13(6):1958-66. PubMed ID: 27054683
[TBL] [Abstract][Full Text] [Related]
37. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
Keinänen O; Sarrett SM; Delaney S; Rodriguez C; Dayts EJ; Capone E; Sauniere F; Ippoliti R; Sala G; Iacobelli S; Zeglis BM
Mol Pharm; 2023 Jun; 20(6):3241-3248. PubMed ID: 37191353
[TBL] [Abstract][Full Text] [Related]
38. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
[TBL] [Abstract][Full Text] [Related]
39. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
[TBL] [Abstract][Full Text] [Related]
40. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
